• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

Zynerba Pharma Looks Like Bad Medicine for Investors

The charts make ZYNE look bearish and not particularly attractive, so avoid.
By BRUCE KAMICH
Jul 23, 2019 | 01:42 PM EDT
Stocks quotes in this article: ZYNE, GWPH

Jim Cramer is wary of Zynerba Pharmaceuticals  (ZYNE) .

"No. If you want this, you want GW Pharmaceuticals (GWPH) ," said Cramer to a caller during the Lightning Round of his "Mad Money" program on Monday.

So, let's check out the charts of ZYNE, to see where it stands.

In this daily bar chart of ZYNE, below, we can see that prices quietly bottomed around $3 in late December. Prices rallied from just $3 to over $16 in less than five months. Since the May zenith, the price of ZYNE has been stuck in a sideways trading range with declining volume. Prices are below the cresting 50-day moving average line, but still well above the rising 200-day line.

The On-Balance-Volume (OBV) line did move up with the price action, but it has leveled off the past six weeks or so. The Moving Average Convergence Divergence (MACD) oscillator has been in a take-profits, sell mode for most of the time since late May. The oscillator looks like it is slipping below the zero-line now for an outright sell signal.

In this weekly bar chart of ZYNE, below, we can see that prices suffered a lengthy decline from 2017 to the end of 2018. The stock price has recovered about half of the prior decline and now the indicators are showing weakness. Prices are above the rising 40-week moving average line but the OBV line looks toppy and the MACD oscillator has crossed to the downside for a take profits sell signal.

In this Point and Figure chart of ZYNE, below, we can see an upside price target of near $15 projected.

Bottom line strategy: ZYNE could bounce to make a third rally failure (May, July and perhaps August) but the 10,000 foot view of ZYNE is bearish and not particularly attractive. Avoid.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are prohibited from trading individual securities.

TAGS: Investing | Technical Analysis | Mad Money | Cannabis

More from Investing

Bearish Bets: 2 Nasdaq Stocks You Should Consider Shorting This Week

Bob Lang
Jan 17, 2021 12:05 PM EST

These names are displaying technical deterioration.

KushCo Sprinkles Some Gems on Its Earnings Call

Debra Borchardt
Jan 17, 2021 8:15 AM EST

The cannabis packaging company is looking at Arizona and New Jersey as new markets for growth.

When it Comes Time to Sell, Will You Act or Will You Freeze?

James "Rev Shark" DePorre
Jan 16, 2021 10:00 AM EST

Why don't more people embrace the ease and power of selling stocks? Why do they freeze and do nothing as losses build?

Cybersecurity Stocks that Lagged in 2020 Could Get Boost from SolarWinds Hack

Eric Jhonsa
Jan 16, 2021 8:00 AM EST

The hack stands to drive an uptick in corporate and government spending to protect both on-premise and cloud assets.

Hungry Traders and Stock Opportunities Aren't Likely to Go Away Soon

James "Rev Shark" DePorre
Jan 15, 2021 4:40 PM EST

It doesn't take much time for stocks with strong momentum to reset and continue on their way.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 09:01 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    When it's time to sell, will you act or freeze?
  • 08:35 AM EST GARY BERMAN

    Wednesday Morning Fibocall for 1/13/2021

    Lower highs... SPX (Long-Term View) The 1/8/2...
  • 08:07 AM EST GARY BERMAN

    Tuesday Morning Fibocall for 1/12/2021

    Watch if the recent trend of lower highs continues...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login